US FDA approves Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma: Princeton, New Jersey Saturday, December 6, 2025, 09:00 Hrs [IST] ...
The Nutraceutical Excipients Market was valued at USD 4.5 billion in 2024, reflecting strong expansion driven by the rising consumption ...
China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...
2d
High-end Refractometer Market worth $0.38 billion by 2032 - Exclusive Report by MarketsandMarkets™
According to MarketsandMarkets™, the global High-end Refractometer Market is projected to grow from USD 0.23 billion in 2025 ...
Berlin, Germany, and Research Triangle Park, N.C., USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media ...
A new law is intended to speed up introduction of advanced sunscreens in the United States The U.S. has fallen behind other ...
Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the oral presentation of positive results ...
Detailed price information for Artara Therapeutics Inc (TARA-Q) from The Globe and Mail including charting and trades.
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
Princeton: Bristol Myers Squibb has received approval for Breyanzi (lisocabtagene maraleucel; liso-cel) from the U.S. Food ...
Former Miami-Dade County Commissioner EILEEN HIGGINS is heading to the Miami mayor’s office, becoming the first Democrat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback